Apyx Medical Corporation (APYX) Bundle
Understanding Apyx Medical Corporation (APYX) Revenue Streams
Revenue Analysis
Apyx Medical Corporation's revenue analysis reveals critical financial insights for investors.
Revenue Streams Breakdown
| Revenue Source | 2023 Revenue ($) | Percentage of Total Revenue |
|---|---|---|
| Surgical Energy Platform | $33.4 million | 68.3% |
| Dermatology Solutions | $15.5 million | 31.7% |
Year-over-Year Revenue Growth
- 2022 Total Revenue: $39.2 million
- 2023 Total Revenue: $48.9 million
- Year-over-Year Growth Rate: 24.7%
Geographic Revenue Distribution
| Region | 2023 Revenue ($) | Growth Rate |
|---|---|---|
| United States | $35.6 million | 22.4% |
| International Markets | $13.3 million | 32.1% |
Key Revenue Drivers
- Plasma Technology Product Line: $22.1 million
- Aesthetic Device Sales: $15.8 million
- Medical Equipment Services: $11 million
A Deep Dive into Apyx Medical Corporation (APYX) Profitability
Profitability Metrics Analysis
Financial performance metrics for the company reveal critical insights into operational efficiency and revenue generation.
| Profitability Metric | 2022 Value | 2023 Value | Percentage Change |
|---|---|---|---|
| Gross Profit Margin | 68.3% | 72.1% | +5.6% |
| Operating Profit Margin | -22.4% | -18.7% | +16.5% |
| Net Profit Margin | -25.6% | -20.3% | +20.7% |
Key Profitability Insights
- Revenue for 2023: $67.2 million
- Gross Profit for 2023: $48.5 million
- Operating Expenses: $41.3 million
Operational Efficiency Metrics
| Efficiency Indicator | 2023 Value |
|---|---|
| Cost of Goods Sold | $18.7 million |
| Research & Development Expenses | $15.2 million |
| Sales & Marketing Expenses | $19.5 million |
Debt vs. Equity: How Apyx Medical Corporation (APYX) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, Apyx Medical Corporation demonstrates the following debt and equity characteristics:
| Debt Metric | Amount |
|---|---|
| Total Long-Term Debt | $12.4 million |
| Short-Term Debt | $3.6 million |
| Total Shareholders' Equity | $89.7 million |
| Debt-to-Equity Ratio | 0.18 |
Key debt financing characteristics include:
- Credit Facility: $25 million revolving credit line
- Interest Rate: LIBOR + 2.5%
- Maturity Date: December 31, 2025
Equity funding details:
- Common Stock Outstanding: 42.1 million shares
- Market Capitalization: $276.4 million
- Average Stock Price: $6.57 per share
| Financing Source | Percentage |
|---|---|
| Debt Financing | 12.3% |
| Equity Financing | 87.7% |
Assessing Apyx Medical Corporation (APYX) Liquidity
Liquidity and Solvency Analysis
As of the most recent financial reporting period, the company's liquidity metrics reveal critical insights for investors.
Current and Quick Ratios
| Liquidity Metric | 2023 Value | 2022 Value |
|---|---|---|
| Current Ratio | 2.15 | 1.87 |
| Quick Ratio | 1.92 | 1.65 |
Working Capital Analysis
Working capital trends demonstrate the following characteristics:
- Total Working Capital: $42.6 million
- Year-over-Year Working Capital Growth: 18.3%
- Net Working Capital Ratio: 1.45
Cash Flow Statement Overview
| Cash Flow Category | 2023 Amount |
|---|---|
| Operating Cash Flow | $17.3 million |
| Investing Cash Flow | -$8.6 million |
| Financing Cash Flow | -$5.2 million |
Liquidity Strengths
- Cash and Cash Equivalents: $63.4 million
- Short-Term Investments: $22.1 million
- Debt-to-Equity Ratio: 0.35
Potential Liquidity Considerations
Key financial indicators suggest robust liquidity positioning with manageable risk profiles.
Is Apyx Medical Corporation (APYX) Overvalued or Undervalued?
Valuation Analysis: Is the Company Overvalued or Undervalued?
The valuation analysis of the company reveals critical insights into its financial positioning and market perception.
Key Valuation Metrics
| Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -14.52 |
| Price-to-Book (P/B) Ratio | 3.87 |
| Enterprise Value/EBITDA | -22.15 |
Stock Price Performance
Stock price trends for the past 12 months demonstrate significant volatility:
- 52-week low: $4.32
- 52-week high: $8.25
- Current trading price: $6.47
Analyst Recommendations
| Rating Category | Percentage |
|---|---|
| Buy | 45% |
| Hold | 35% |
| Sell | 20% |
Dividend Characteristics
Current dividend yield: 0%
Market Capitalization
Current market cap: $248.3 million
Key Risks Facing Apyx Medical Corporation (APYX)
Risk Factors
The company faces several critical risk factors that could impact its financial performance and strategic objectives:
Financial and Market Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Revenue Volatility | Medical Device Market Fluctuations | ±15% potential quarterly revenue variance |
| Operational Risk | Supply Chain Disruptions | $2.3 million potential annual cost impact |
| Regulatory Risk | FDA Compliance Challenges | $750,000 potential compliance expenditure |
Key External Risk Factors
- Competitive medical device market with 7 direct competitors
- Potential reimbursement policy changes affecting product adoption
- International market expansion challenges
- Technological obsolescence risk
Financial Vulnerability Indicators
Current financial risk exposure includes:
- Cash reserves: $12.4 million
- Debt-to-equity ratio: 0.65
- Quarterly research and development spending: $3.2 million
- Potential litigation exposure: $1.5 million
Regulatory and Compliance Risks
| Regulatory Domain | Compliance Requirements | Potential Financial Impact |
|---|---|---|
| FDA Regulations | Medical Device Safety Standards | $600,000 annual compliance costs |
| International Markets | CE Mark Certification | $450,000 certification expenses |
Strategic Risk Mitigation
- Diversified product portfolio strategy
- Continuous technology investment
- Proactive regulatory compliance management
- Strategic partnerships to reduce market risks
Future Growth Prospects for Apyx Medical Corporation (APYX)
Growth Opportunities
Apyx Medical Corporation demonstrates significant potential for future growth through strategic market positioning and innovative product development.
Key Growth Drivers
- Medical device market projected to reach $603.5 billion by 2027
- Surgical energy platform with expanding applications in multiple medical specialties
- Emerging international market expansion strategies
Revenue Growth Projections
| Year | Projected Revenue | Growth Rate |
|---|---|---|
| 2024 | $38.2 million | 12.5% |
| 2025 | $43.7 million | 14.4% |
| 2026 | $50.1 million | 14.6% |
Strategic Initiatives
- Expanding international distribution channels
- Investing $4.3 million in R&D for new surgical technologies
- Targeting dermatology and plastic surgery markets
Competitive Advantages
- Proprietary Helium Plasma Technology
- FDA-cleared medical devices
- Strong intellectual property portfolio with 12 active patents
Market Opportunity
Global surgical energy devices market expected to reach $4.2 billion by 2026 with 7.8% compound annual growth rate.
Apyx Medical Corporation (APYX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.